Provided by Tiger Trade Technology Pte. Ltd.

LAEKNA-B

6.300
-0.340-5.12%
Volume:862.00K
Turnover:5.47M
Market Cap:2.85B
PE:-10.68
High:6.490
Open:6.490
Low:6.230
Close:6.640
52wk High:19.600
52wk Low:5.370
Shares:452.00M
HK Float Shares:452.00M
Volume Ratio:0.60
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.590
ROE:-10.69%
ROA:-7.60%
PB:2.03
PE(LYR):-10.68
PS:9.48

Loading ...

Laekna Issues 2.73 Million New Shares for RSU Vesting, Lifting Share Count by 0.61%

Bulletin Express
·
Sep 08

LAEKNA-B Issues 273,000 Shares to Settle RSU Vesting Under 2024 Equity Incentive Plan

Stock News
·
Sep 08

Laekna Files HKEX Next-Day Disclosure, Issues 2.73 Million New Shares to Lift Share Capital

Reuters
·
Sep 08

Laekna Maintains 449.33 Million Shares Outstanding in August 2026, Confirms Adequate Public Float

Bulletin Express
·
Sep 04

HK Stocks in Focus: LAEKNA-B (02105) Jumps Over 9% in Early Trading After First Patient Dosed in Phase I Trial

Stock News
·
Sep 01

LAEKNA-B Initiates First-Patient Dosing in Phase I Trial of LAE118, a Novel Pan-Mutant-Selective PI3Kα Inhibitor

Stock News
·
Sep 01

Laekna Enrolls First Patient in China Phase I Trial of Cancer Drug Candidate Lae118

Reuters
·
Sep 01

Analysts Just Made A Significant Upgrade To Their Laekna, Inc. (HKG:2105) Forecasts

Simply Wall St.
·
Aug 28

LAEKNA-B Announces Interim Results with Other Income Climbing 30.41% Year-on-Year

Deep News
·
Aug 26

LAEKNA-B (02105) Posts Interim Results: Other Income Up 30.41% to RMB 25.962 Million

Stock News
·
Aug 25

Laekna FY26 H1 Net Loss Narrows to RMB 2.55 Million; Revenue Rises to RMB 150.28 Million

Reuters
·
Aug 25

Laekna forecasts up to RMB155.00 million H1 2026 revenue, trims net loss by 96%

Bulletin Express
·
Aug 17

Laekna Expects H1 Net Loss no More than RMB 5 Million

Reuters
·
Aug 17

Laekna - Expects Revenue of Rmb145 Mln-Rmb155 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS
·
Aug 17

LAEKNA-B's LAE002 NDA Accepted by CDE, Signaling a Domestic AKT Inhibitor Major Launch

Stock News
·
Aug 13

Laekna Breast Cancer Drug NDA Accepted in China

MT Newswires Live
·
Aug 12

New Drug Application for Lae002 (Afuresertib) Accepted by China's National Medical Products Administration

THOMSON REUTERS
·
Aug 12

Laekna gains NMPA nod to review NDA for AKT inhibitor Afuresertib in HR+/HER2- breast cancer

Bulletin Express
·
Aug 12

Laekna Says China Regulator Accepts NDA for Afuresertib in Hr+/her2- Breast Cancer

Reuters
·
Aug 12

Laekna - Nda for Lae002 (Afuresertib) Accepted by China's Nmpa for Hr+/Her2- Breast Cancer

THOMSON REUTERS
·
Aug 12